Actinium Pharmaceuticals Inc ATNM:NYSE American

Last Price$7.29AMEX Previous Close - Last Trade as of 5:00PM ET 11/26/21

Today's Change0(0.00%)
Bid (Size)$7.20 (1)
Ask (Size)$7.29 (3)
Day Low / HighN/A - N/A
Volume61.6 K

View Biotechnology IndustryPeer Comparison as of 11/26/2021


Actinium Pharmaceuticals Inc ( NYSE MKT LLC )

Price: $7.29
Change: -0.11 (1.49%)
Volume: 61.6 K
5:00PM ET 11/26/2021

Equillium Inc ( NASDAQ )

Price: $5.41
Change: +0.02 (0.37%)
Volume: 33.7 K
12:59PM ET 11/26/2021

MediciNova Inc ( NASDAQ )

Price: $3.22
Change: -0.35 (9.80%)
Volume: 473.7 K
1:00PM ET 11/26/2021

Enzo Biochem Inc ( NYSE )

Price: $3.38
Change: +0.04 (1.20%)
Volume: 153.3 K
5:00PM ET 11/26/2021

NextCure Inc ( NASDAQ )

Price: $6.02
Change: -0.18 (2.90%)
Volume: 116.6 K
1:00PM ET 11/26/2021

Read more news Recent News

Actinium Pharmaceuticals Completes Enrollment in Phase 3 Trial of Iomab-B to Treat Leukemia; Shares Gain Pre-Bell
8:53AM ET 9/15/2021 MT Newswires

Actinium Pharmaceuticals (ATNM) said Wednesday it has completed enrolling subjects in a phase 3 trial evaluating Iomab-B as a potential treatment of...

--HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $45 From $57, Maintains Buy Rating
6:38AM ET 8/03/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Actinium Pharmaceuticals Awarded Patents in Europe, Japan for Antibody Radiation Conjugate
10:51AM ET 6/17/2021 MT Newswires

Actinium Pharmaceuticals (ATNM) said Thursday it has been awarded patents in Europe and Japan for the composition and methods of administering its Iomab-B...

--Analyst Actions: HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $57 From $65, Maintains Buy Rating
11:02AM ET 4/01/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Actinium: A Story Of Delays And Promises, About To Come To Fruition
9:21AM ET 7/15/2021 Seeking Alpha

3 Investment Mistakes I've Made (So You Don't Have To)
9:46AM ET 4/22/2021 Seeking Alpha

The Verdict On Actinium Pharmaceuticals
2:58PM ET 3/05/2021 Seeking Alpha

Wall Street Breakfast: What Moved Markets
11:02AM ET 1/02/2021 Seeking Alpha

Company Profile

Business DescriptionActinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company was founded in 2002 and is headquartered in New York, NY. View company web site for more details
Address275 Madison Avenue
New York, New York 10016
Number of Employees30
Recent SEC Filing11/12/202110-Q
Chairman & Chief Executive OfficerSandesh Seth
Chief Financial OfficerSteve O'Loughlin
Chief Medical OfficerAvinash Desai
Vice President-Clinical DevelopmentMary Mei Chen

Company Highlights

Price Open$7.29
Previous Close$7.40
52 Week Range$5.70 - 11.90
Market Capitalization$160.6 M
Shares Outstanding22.0 M
SectorHealth Technology
Next Earnings Announcement03/30/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.27
Beta vs. S&P 500N/A
Net Profit Margin-2,506.87%
Return on Equity-34.52%

Analyst Ratings as of 09/14/2021

Consensus RecommendationConsensus Icon
Powered by Factset